Faculty profile
Robert Kozak
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Université Laval directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $44,460
COVID-19 Variant Supplement - Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
CIHR · 2021 · Principal investigator
- $999,356
Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
CIHR · 2020 · Principal investigator
- $1,402,860
Development of an animal model, a protective vaccine and monoclonal antibodies against Crimean-Congo Hemorrhagic Fever Virus
CIHR · 2016 · Co-investigator
COVID-19 Variant Supplement - Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
Principal investigators: Kobinger, Gary P; Kozak, Robert A; Wong, Gary C
Keywords: Animal Model; Immunogenicity; Monoclonal Antibodies; Vaccine
Development of vaccine candidates and monoclonal antibodies to interrupt the spread of the novel coronavirus, COVID-19.
Principal investigators: Kobinger, Gary P; Kozak, Robert A; Wong, Gary C
Keywords: Animal Model; Immunogenicity; Monoclonal Antibodies; Vaccine
Development of an animal model, a protective vaccine and monoclonal antibodies against Crimean-Congo Hemorrhagic Fever Virus
Principal investigators: Kobinger, Gary P
Keywords: Monoclonal Antibodies; Non-Human Primate Model; Pathogenesis; Small Animal Models; Vaccine; Viral Hemorrhagic Fever
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.